Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.-Reference-Cited by-同舟云学术

Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:5510-5510
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Varga Andrea¹,Piha-Paul Sarina Anne²,Ott Patrick Alexander³,Mehnert Janice M.⁴,Berton-Rigaud Dominique⁵,Johnson Elizabeth A.⁶,Cheng Jonathan D.⁶,Yuan Sammy⁶,Rubin Eric H.⁶,Matei Daniela E.⁷

Affiliation:

1. Gustave Roussy Institute, Villejuif, France

2. The University of Texas MD Anderson Cancer Center, Houston, TX

3. Dana-Farber Cancer Institute, Boston, MA

4. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

5. ICO Centre René Gauducheau, Saint-Herblain, France

6. Merck & Co., Inc., Kenilworth, NJ

7. Indiana University, Indianapolis, IN

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.5510

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives;Frontiers in Immunology;2024-08-29

2. Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth;Cancer Immunology, Immunotherapy;2024-03-30

3. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer;Cell Reports Medicine;2023-07

4. The Roles of Exosomes in Ovarian Cancer Chemo-resistance;Journal of Cancer;2023

5. Immunotherapy in gynecologic malignancies;DiSaia and Creasman Clinical Gynecologic Oncology;2023